tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jan 20.
doi: 10.1002/jmv.27613. Online ahead of print.
Characteristics of the first 1,119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021
Linda Houhamdi[SUP] 1 [/SUP], Philippe Gautret[SUP] 1 2 [/SUP], Van Thuan Hoang[SUP] 3 [/SUP], Pierre-Edouard Fournier[SUP] 1 2 [/SUP], Philippe Colson[SUP] 1 4 [/SUP], Didier Raoult[SUP] 1 4 [/SUP]
Affiliations
Abstract
1,119 cases of SARS-CoV-2 Omicron variant cases have been diagnosed at IHU Méditerranée Infection, Marseille, France, between November 28, 2021 and December 31, 2021. Among the 825 patients with a known vaccination status, 383 (46.4%) were vaccinated of whom 91.9% had received at least two doses of the vaccine. Interestingly, 26.3% of cases developed SARS-CoV-2 infection within 21 days following the last dose of vaccine suggesting possible early production of anti-SARS-CoV-2 facilitating antibodies. Twenty-one patients have been hospitalized, one patient required intensive care and another patient who received a vaccine booster dose died. This article is protected by copyright. All rights reserved.
Keywords: Disease control; Epidemiology; Infection; SARS coronavirus; Vaccines/Vaccine strains; Virus classification.
. 2022 Jan 20.
doi: 10.1002/jmv.27613. Online ahead of print.
Characteristics of the first 1,119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021
Linda Houhamdi[SUP] 1 [/SUP], Philippe Gautret[SUP] 1 2 [/SUP], Van Thuan Hoang[SUP] 3 [/SUP], Pierre-Edouard Fournier[SUP] 1 2 [/SUP], Philippe Colson[SUP] 1 4 [/SUP], Didier Raoult[SUP] 1 4 [/SUP]
Affiliations
- PMID: 35060146
- DOI: 10.1002/jmv.27613
Abstract
1,119 cases of SARS-CoV-2 Omicron variant cases have been diagnosed at IHU Méditerranée Infection, Marseille, France, between November 28, 2021 and December 31, 2021. Among the 825 patients with a known vaccination status, 383 (46.4%) were vaccinated of whom 91.9% had received at least two doses of the vaccine. Interestingly, 26.3% of cases developed SARS-CoV-2 infection within 21 days following the last dose of vaccine suggesting possible early production of anti-SARS-CoV-2 facilitating antibodies. Twenty-one patients have been hospitalized, one patient required intensive care and another patient who received a vaccine booster dose died. This article is protected by copyright. All rights reserved.
Keywords: Disease control; Epidemiology; Infection; SARS coronavirus; Vaccines/Vaccine strains; Virus classification.